Skip to content

Weekday Japan business intelligence for finance professionals.

Join the list
Tokyo Brief東 京 ブ リ ー フJapan's day, wrapped and delivered by morning.
Company3 articles
Companies

Kringle Pharma,Inc.

Latest Tokyo Brief coverage on Kringle Pharma,Inc., tracking filings, financial news, and market signals from Japan.

Code
4884
Exchange
TSE
Coverage
3 articles

Latest coverage

TSE:4884

  1. Kringle Pharma's US trial application for spinal-injury drug takes effect

    Kringle Pharma said the FDA review of its IND for oremepermin alfa has ended and the application is in effect; the company is preparing a US Phase III trial in acute spinal cord injury, with no partner or start date named.

  2. Kringle Pharma Asks FDA to Clear US Trial of Spinal-Injury Protein Drug

    The Osaka biotech's IND filing asks the FDA to clear a US Phase III trial of oremepermin alfa, its lab-made HGF protein already tested through Phase III in Japan for acute spinal cord injury, with the US study not yet started.

  3. Kringle Pharma Narrows Loss Forecast After Signing Maruishi Licensing Deal

    Kringle Pharma raised its annual sales guidance and narrowed its projected loss for the year to September 2026 after signing an exclusive Japan licensing deal with Maruishi Pharmaceutical for an experimental vocal-fold-scar treatment, under which it will record a ¥100 million upfront fee as revenue this fiscal year, with roughly half of the improved loss forecast coming instead from ¥108 million of development spending that shifted into next year.